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LESSON LEARNED: WHY FEDERAL STEM 
CELL POLICY MUST BE INFORMED BY 
MINORITY DISADVANTAGE IN ORGAN 
ALLOCATION 
Margaret Bichler* 
WHOSE BODY IS IT ANYWAY? JUSTICE AND THE INTEGRITY OF 
THE PERSON. By Cécile Fabre. New York: Oxford University Press. 
2006. Pp. 268. 
Abstract: Ever since advancements in medical technology made organ 
transplantation possible, the demand for organs has been far greater than 
the supply, thus creating an organ shortage. The medical necessity of ge-
netic matching between donor and donee has disadvantaged minorities in 
their pursuit of healthy organs because most organ donors are Caucasian 
and are therefore not a genetic “match” for minorities. Minority disadvan-
tage in organ allocation must inform federal stem cell policy lest the same 
genetic incompatibility hinder minority access to potentially life-saving 
stem cell therapies. The federal government must take affirmative and 
timely steps in order to ensure equitable access to stem cell therapies in 
the future. This book review outlines those steps, arguing that Congress 
should: (1) fund stem cell research in order to secure march-in rights un-
der the Bayh-Dole Act; and (2) condition the receipt of funds on the use 
of diverse stem cell lines in order to promote the creation of therapies ge-
netically accessible to a diverse citizenship. 
Introduction 
As members of societies that have a history of ethnic discrimination, we 
have an obligation to reduce ethnic disparities in life expectancy and other 
indicators of health. Insofar as these disparities are understood as present 
injustices, at the very least, public policy should not be formulated in ways 
that make them worse. 
—Ruth R. Faden1 
                                                                                                                      
* Staff Writer, Boston College Third World Law Journal (2006–2007). 
1 Ruth R. Faden, Public Stem Cell Banks: Considerations of Justice in Stem Cell Research and 
Therapy, 33 Hastings Center Rep. 13, 22 (2003). Faden is professor of Biomedical Ethics 
and Executive Director of The Berman Institute of Bioethics at the Johns Hopkins Univer-
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 In recent years, as organ transplantation has progressed and be-
come a safer practice, the demand for organs has increased while the 
supply has remained the same.2 Unfortunately, in the resulting organ 
shortage, minority and impoverished populations have been both dis-
advantaged in their pursuit of organs and exploited by the organ trade 
that exists in foreign countries.3 This situation has left many pondering 
what social justice requires given such a shortage.4 Further scientific 
advancement has made the medical community newly hopeful that 
stem cells—unspecialized, raw biological materials capable of develop-
ing into numerous more specialized cells, such as muscle, heart, nerve, 
and blood—will one day render the organ shortage a crisis of the past.5 
As research efforts progress, and social debate continues, one thing 
seems certain: insofar as stem cell research promises to bridge the gap 
between organ supply and demand, sound federal policy must be im-
plemented now in order to guide the research efforts and to ensure 
equitable distribution of its fruits in the future.6 
 Cécile Fabre, author of Whose Body Is It Anyway? Justice and the Integ-
rity of the Person, explores the organ shortage within a broader discus-
sion of social justice.7 She defines a just society as one in which: (1) 
every citizen has the resources necessary to lead a minimally flourishing 
life, and (2) once everybody has such a life, individuals are allowed to 
“enjoy the fruits of their labor in pursuit of their conception of the 
                                                                                                                      
sity. Johns Hopkins Berman Institute of Bioethics: People, http://www.hopkinsmedicine. 
org/bioethics/people/personnel/faden.html (last visited Mar. 15, 2007). She is also a Senior 
Research Scholar at the Kennedy Institute of Ethics at Georgetown University and author 
of numerous books and articles on biomedical ethics and health policy. Id. Her article, 
Public Stem Cell Banks: Considerations of Justice in Stem Cell Research and Therapy, is relied on 
throughout this book review primarily because Faden is both an expert and a pioneer in 
the field of stem cell policy. 
2 See Eric F. Galen, Organ Transplantation at the Millennium: Regulatory Framework, 
Allocation Prerogatives, and Political Interests, 9 S. Cal. Interdisc. L.J. 335, 335 (1999). 
3 See id. at 363; Poor Villagers Fall Prey to Kidney Trade, China Daily, Aug. 16, 2006, available 
at http://english.peopledaily.com.cn/200608/16/eng20060816_293544.html [hereinafter 
Poor Villagers]; Trupti Patel, TED Case Studies: India Kidney Trade, Jan. 1996, http://www. 
american.edu/ted/class/all.htm#Jan1996 (follow “Human Kidney Trade, by Trupti Patel” 
hyperlink) (outlining the Indian kidney trade and the organ shortage). 
4 See, e.g., Cécile Fabre, Whose Body Is It Anyway? Justice and the Integrity of 
the Person 5 (2006); Patel, supra note 3; Inst. of Med. of the Nat’l Acads., Report 
Brief: Organ Donation: Opportunities for Action 1 (2006), available at http://www. 
iom.edu/Object.File/Master/34/281/Organ%20Donation%20for%20web.pdf [hereinafter 
Report Brief]. 
5 See Faden, supra note 1, at 13. 
6 See id. 
7 See Fabre, supra note 4, at 5. 
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good.”8 To achieve the first prong, Fabre proposes that just as individu-
als in a just society have equal rights to the material resources necessary 
to lead a minimally flourishing life, they have equal rights to personal 
resources—namely, body parts and personal services (e.g., acts of good 
samaritanism, prostitution, surrogacy).9 Based on this understanding, 
she seeks to show that, insofar as the government has access to one’s 
material resources via taxation for the purpose of redistributing those 
resources to the poor, the government should also have access to per-
sonal resources, namely healthy and able bodies and body parts, for the 
purpose of redistributing organs to the sick or for imposing a duty to 
act on a third person who witnesses another’s peril.10 In order for the 
second prong to be satisfied, that is, in order for individuals to be freely 
able to pursue their conception of the good, Fabre suggests that indi-
viduals should be legally permitted to sell their organs and to lease 
their bodies for child-bearing or sexual services.11 Here Fabre explains 
that organ sales, surrogacy contracts, and prostitution, should be legal 
for different reasons: though they are not necessities required by all in 
order to lead a minimally flourishing life, they are desired by some in 
their pursuit of an ideal existence, which is equally important in a just 
                                                                                                                      
8 Id. at 4. Fabre defines a minimally flourishing life as one in which an individual is ca-
pable of “framing, revising, and implementing a conception of the good” with which she 
identifies. Id. at 32. Obtaining such a life requires that one has a “range of opportunities to 
choose from, and access—time and resources—to some of those opportunities.” Id. Fabre 
then explains that the principle of sufficiency requires steps to be taken (redistributive 
steps) to provide individuals with the means necessary to lead a minimally flourishing life, 
namely that poor people are given basic necessities, that individuals are given access to 
financial services and to markets, and that social services are provided. Id. at 33. Achieving 
sufficiency requires that the autonomy of some is compromised as distributive policies 
deprive them of some resources for the betterment of others. Id. 
9 Id. at 7–8. Fabre asserts that organ confiscation from both dead and live bodies 
should be legalized. Id. at 5. Essentially, the viable organs from every dead body would be 
harvested and donated. Id. at 73–74. Citizens would also be commissioned to donate or-
gans such as kidneys, corneas, and liver lobes while living if and when they were deter-
mined to be a match for someone in need. See id. at 100. 
10 Id. at 2–3. Fabre argues for a “highly qualified right to personal integrity” and, in so 
doing, suggests that personal autonomy and broader access to others’ bodies can and 
should co-exist. Id. at 2. The author proposes that “being committed to coercive taxation 
for the purpose of distributive justice does entail that we cannot be committed to a full 
right to personal integrity . . . rejecting the view that individuals have such a right does not 
entail sacrificing one of liberalism’s core values . . . to wit, autonomy.” Id. at 3. For Fabre, 
body parts, though not commodities, are resources that are needed by some, for example 
those who suffer renal failure, to lead a minimally flourishing life. See id. at 5. Similarly, 
other citizens who find themselves in peril have an equal right to the personal services of 
an able-bodied bystander capable of helping without accepting an unreasonable risk or 
compromising their own ability to achieve a minimally flourishing life. Id. at 4. 
11 Id. at 8–9. 
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society.12 Anticipating criticism that the legalization of organ sales 
would ultimately exploit the poor, Fabre situates her argument within 
“ideal theory” —a theory of distributive justice that assumes every citi-
zen’s need for material resources is met, or, in other words, that there is 
no poverty.13 
 While Fabre’s arguments are interesting, their utility, at least in the 
United States, is limited by both the tremendous value consistently 
placed on personal autonomy by the American legal system and the 
reality of poverty.14 The value and preservation of personal autonomy 
informs so much of the American legal landscape that it is difficult, if 
not impossible, to imagine a government willing and able to confiscate 
organs from its citizens.15 Moreover, poverty plagues the United States 
and other capitalistic societies, and the legalization of organ sales would 
inevitably result in the exploitation of poor populations.16 In fact, in 
countries where organ sales are currently legal, impoverished citizens 
sell organs for minimal compensation to their more economically sta-
ble counterparts.17 Despite the limitations that the value of autonomy 
and poverty place on Fabre’s arguments, the author is simply seeking to 
outline a solution to a very real problem that has come to haunt both 
national and international medical fields within recent years: the organ 
shortage.18 
 Given the value of personal autonomy and the pervasiveness of 
poverty, this Book Review provides a more realistic examination of the 
                                                                                                                      
12 Fabre, supra note 4, at 8–9. 
13 Id. at 8. Fabre realizes that examining organ sales in ideal theory is odd because 
standard objections to the legalization of organ sales are based on the fact that there is 
poverty and, as a result, poor people might have no choice but to sell an organ in order to 
meet their financial and material needs. Id. She goes on to explain that, even if there is 
reason to believe that organ sales would be less prevalent in a just society, the question of 
their legitimacy would not be completely moot because individuals, she argues, should still 
have the right regardless of whether or not they exercise it. Id. 
14 See, e.g., Thor v. Superior Court, 855 P.2d 375, 380 (Cal. 1993); In re Gardner, 534 A.2d 
947, 950 (Me. 1987) (explaining that “American courts and commentators have long empha-
sized the importance of personal autonomy”); U.S. Census Bureau, Poverty: 2005 Highlights, 
http://www.census.gov/hhes/www/poverty/poverty05/pov05hi.html (last visited Mar. 22, 
2007) [hereinafter Poverty Highlights]. The official poverty rate in 2005 was 12.6%. Id. The 
poverty rate was 24.9% among Blacks and 21.8% among Hispanics. Id. 
15 See Thor, 855 P.2d at 380; Gardner, 534 A.2d at 950. 
16 Poverty Highlights, supra note 14. 
17 See Poor Villagers, supra note 3; Patel, supra note 3. 
18 See Report Brief, supra note 4, at 1 (explaining that “as organ transplantation has 
grown increasingly safe and effective, the demand for transplants has grown far faster than 
the supply of available organs”). The number of people on the U.S. waiting lists has in-
creased from 16,000 in 1988 to a current total of more than 90,000; approximately 40,000 
individuals are added to the transplant waiting list every year. Id. 
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shortage and assesses the need for federal stem cell policy that recog-
nizes the ways in which both minority and poor populations are disad-
vantaged in their pursuit of healthy organs. It will evaluate the need for 
federal safeguards against the disadvantage of these populations if and 
when stem cell research bridges the gap between the supply and de-
mand of organs. The federal government has already created a niche 
within the scheme of federally funded research via the Bayh-Dole Act of 
1980, which creates the right of private research entities to patent fed-
erally funded research, but reserves a right for the government to 
“march-in” if the results of that research are not used for the good of 
the general public.19 
 Part I will outline the ways in which the organ shortage adversely 
affects minority and poor populations both domestically and abroad.20 
Part II will discuss stem cell research and the probability that, if left un-
regulated, its fruits will benefit primarily wealthy Caucasian popula-
tions.21 Because of these risks, it is imperative that the federal govern-
ment does what it can to direct stem cell research.22 Part III will 
introduce the Bayh-Dole Act as a means by which the federal govern-
ment could provide meaningful guidance to stem cell research efforts 
to ensure that, if those efforts one day minimize the gap between organ 
supply and demand, the benefits of such scientific advancements will 
be enjoyed equitably.23 Part III will outline the necessary steps to ensure 
equal access to future stem cell therapies: (1) Congress must pass legis-
lation allocating federal funds to stem cell research, (2) the National 
Institutes of Health (NIH), or comparable federal entities, must estab-
lish stem cell banks comprised of diverse stem cell lines, and (3) Con-
gress must condition the provision of federal funds on the use of di-
verse stem cell lines in research.24 
                                                                                                                      
19 Bayh-Dole Act of 1980, 35 U.S.C. § 203(a) (2001). The Act stipulates that when the 
federal government funds research conducted by a nonprofit organization or a small busi-
ness firm, the contractor has a right to patent the results. Id. § 202. With respect to any 
resulting invention, the funding agency shall have the right to require the patent holder to 
grant a license to the government or the government’s designee. Id. § 203. 
20 See, e.g., Galen, supra note 2 at 363; Patel, supra note 3; Poor Villagers, supra note 3. 
21 See Faden, supra note 1, at 14. 
22 See id. 
23 See 35 U.S.C. § 203(a); Faden, supra note 1, at 14. 
24 Steve Mitchell, United Press Int’l, U.S. Stem Cell Firms Moving Overseas, Aug. 8, 2006, 
available at http://www.spacedaily.com/reports/US_Stem_Cell_Firms_Moving_Overseas_ 
999.html (explaining that President Bush’s recent veto of federal legislation that would have 
funded stem cell research on frozen embryos has influenced stem cell research firms to relo-
cate overseas to more favorable research forums); Press Release, Johns Hopkins Medicine, 
Panel: Clinical Use of Embryonic Stem Cells Jeopardized by Policy on Federal Funding (Nov. 
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I. Minority and Poor Disadvantage in the Organ Shortage 
 The organ shortage is a frustrating and heartbreaking reality for 
all involved, but it is most costly for members of poor and minority 
populations.25 There are at least three ways in which the organ shortage 
harms minorities and the poor: (1) allocation protocol coupled with 
biological issues of genetic matching in the United States leaves minori-
ties waiting for organs longer and in greater numbers, (2) the cost of 
organ transplantation prevents the poor from obtaining organ trans-
plants, and (3) impoverished populations abroad are exploited by 
wealthy organ donees who buy their organs for minimal compensa-
tion.26 In the United States, African Americans and other minorities are 
on organ waiting lists in greater percentages and for longer periods of 
time than their white counterparts.27 Inasmuch as the following reasons 
for minority disadvantage center on biological issues and the failure of 
African Americans to donate organs in high numbers, the federal gov-
ernment is in no position to remedy the disadvantage.28 However, the 
federal government currently stands in the ideal position from which to 
direct stem cell research so that these issues will not result in minority 
disadvantage in the future allocation of stem cell therapies. 
 There are numerous reasons for minority disadvantage in organ 
allocation in the United States.29 First, minority populations and Cau-
                                                                                                                      
10, 2003), available at http://www.hopkinsmedicine.org/Press_releases/2003/11_10_03. 
html (explaining that President Bush’s decision in 2001 to limit the use of federal funds to 
research of existing stem cell lines has seriously impinged efforts in the field). 
25 See, e.g., Galen, supra note 2, at 363–64 (explaining the ways in which African Ameri-
cans are disadvantaged in the United States’ organ allocation scheme); Poor Villagers, supra 
note 3 (discussing the Pakistani impoverished populations that are promised jobs in ex-
change for their kidneys); Patel, supra note 4 (describing the ways in which poor and mi-
nority populations in India sell kidneys for minimal funds to wealthy foreigners). 
26 South Dakota v. Dole, 483 U.S. 203, 206–07 (1987); Ivanhoe Irrigation Dist. v. 
McCracken, 357 U.S. 275, 295 (1958); see also United States v. Butler, 297 U.S. 1, 65 (1936) 
(interpreting broadly the spending power, and establishing the constitutionality of the 
conditional grant of federal funds). 
27 See, e.g., Galen, supra note 2, at 363; Robert S. Gaston, Addressing Minority Issues in 
Renal Transplantation: Is More Equitable Access an Achievable Goal? 2 Am. J. of Transplanta-
tion 1 (2002); Minority Donation Educ. Alliance (MDEA), Did You Know?, available at 
http://www.mdeda.org/info.asp (last visited Mar. 22, 2007) (providing statistical data on 
the current dearth of organ donations made by minorities in America and on-average 
waiting list times for minority organ donees relative to Caucasian donees). 
28 See Galen supra note 2, at 363–64. 
29 See id. Much of this “disparate medical phenomenon” has been caused by both bio-
logic factors and allocation priorities. Id. at 363. Compared to whites, African Americans 
suffer approximately four times greater incidence of end stage renal disease. Id. Conse-
quently, a disproportionately high number of African Americans are in need of kidney 
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casians are genetically dissimilar in immune system antigens and blood 
types, which translates into immune system incompatibilities that pre-
vent minorities from passing the initial screening by which genetic 
“matches” are paired according to allocation protocol.30 Second, fewer 
African Americans than Caucasians elect to become organ donors, 
which results in Caucasians having a greater likelihood of being suc-
cessfully matched to a donor sooner.31 Third, even with governmental 
guidelines in place to secure equitable distribution of organs, all organ 
allocations are subject to “medical judgments” concerning the suitabil-
ity of donees for the transplant.32 Minority populations are, therefore, 
left unprotected against discriminatory judgment calls that they are 
unlikely to lead a life conducive to caring for a healthy organ.33 
 The tremendous cost of an organ transplant disadvantages an-
other marginalized population in their pursuit of healthy organs: the 
poor.34 It is estimated that, in the United States, an organ transplant 
procedure and the necessary post-operation medical care costs as much 
                                                                                                                      
transplants; “African Americans comprise approximately twelve percent of the United 
States population, and thirty-two percent of the kidney waiting list.” Id. 
30 See id. at 363–64. Biologic differences, like the dissimilarities in immune system anti-
gens and blood types existing between African Americans and Caucasians, between a do-
nor and a donee, can trigger immune responses from the donee’s body after transplanta-
tion causing transplant failure or death. Id. Specifically, blood types O and B are more 
common among African Americans than whites, and since whites are more frequently 
organ donors, this results in African Americans on the waiting list failing the initial Match 
System screening when organs from white donors are allocated. Id. at 364. 
Gaston explains that because immunosuppression technology (used to suppress im-
mune rejection of organs that are of a different genetic type than the donee’s) has become 
more advanced, the importance of genetic matching to successful transplant outcomes has 
been greatly reduced. Gaston, supra note 27, at 2. The impact of HLA-based allocation, the 
process by which human leukocyte antigens are matched between donor and donee in 
order to increase the likelihood of successful transplantation, is to offer rapid transplanta-
tion to those with common antigens and reduce access for minorities with uncommon 
antigens. See id. A recent study suggests that reducing reliance on ABO blood-type identity 
and HLA matching might increase minority access to transplantation by as much as fifteen 
percent. Id. 
31 MDEA, Home/About Us, http://www.mdeda.org/ (last visited Mar. 22, 2007). 
32 See Galen, supra note 2, at 375–77. Galen discusses a scenario in which a doctor 
might make a judgment call between a healthy, wealthy white male and an alcoholic 
woman when determining who should get a liver. Id. Galen speculates that the doctor 
might ultimately decide that the healthy, wealthy white male, promising to make a large 
donation to the hospital, will get the liver because the woman’s alcoholism makes her less 
medically suitable given that her lifestyle induced the failure of her own liver. Id. The same 
discretionary judgments can be made to disfavor African Americans and other minority 
populations whom, the doctor may assume, also lead unacceptable lifestyles. See id. 
33 See id. 
34 Id. at 368. 
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as $394,000 per patient.35 While most states have Medicaid programs 
that cover the majority of transplant procedures, many individuals are 
not poor enough to qualify for Medicaid, cannot afford private health 
insurance, and cannot conceivably produce nearly $400,000 for a life-
saving organ transplant—their precarious financial situation will proba-
bly leave them on the waiting list indefinitely.36 Moreover, wealthy 
Americans can remove themselves from organ transplant waiting lists 
by flying overseas and securing an organ transplant for a mere $130,000 
to $160,000.37 The poor cannot because Medicaid and other insurance 
providers will not cover an organ transplant in a foreign black market; 
as a result, the availability of an organ market abroad provides the 
wealthy with another advantage and leaves the poor waiting longer for 
organs.38 
 The organ shortage does not just harm people of color in need of 
transplants; it also leads to the exploitation of minority organ “donors” 
in foreign markets.39 This unsettling reality must also inform federal 
stem cell policy so that the economic incentive to purchase organs 
abroad will cease once stem cell therapies are developed.40 In countries 
where organ sales are legal or where they are illegal but proliferate via 
the black market, the situation of the poor within the organ shortage is 
exacerbated as they are exploited by wealthy counterparts seeking 
healthy organs.41 The following account of Amjad Ali, a poor villager 
from eastern Pakistan who was promised a job and money in exchange 
                                                                                                                      
35 Id. 
36 See id. 
37 See A Chinese Horror Story, St. Louis Post-Dispatch, Aug. 22, 2006, available at http:// 
www.clearwisdom.net/emh/articles/2006/8/27/77373.html. 
38 See id. 
39 See id. 
40 See 35 U.S.C. § 203(a) (2001). Insofar as the government retains the right to “march-
in” if the technology is not being used for the public good, if federal funding is provided 
to stem cell research now, the government can probably ensure the affordability of stem 
cell therapies in the future, thus removing the incentive for purchasing organs abroad. See 
id. 
41 Poor Villagers, supra note 3. In January of 1995, the reality of the organ trade and the 
potential for exploitation was realized; the kidney scandal first came into the public eye 
when three different underground operations were discovered, all driven by the kidney 
shortage. Patel, supra note 3. Customs officers in Delhi uncovered a “kidney tour” racket in 
which hundreds of donors had been enticed to go abroad for removal and transplantation 
of their kidneys. Id. Authorities next discovered residents of a leprosy colony selling kid-
neys for money. Id. Finally, police in Banglore busted a massive racket in which the kidneys 
of an estimated one thousand individuals had been removed without their knowledge in a 
leading city hospital where the individuals had been lured with offers of jobs and for the 
purpose of giving blood. Id. 
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for one of his kidneys, is a striking example of the exploitative black 
market.42 Ten months after the procedure, Ali was still jobless, one kid-
ney short, and in constant pain and discomfort.43 He describes his ex-
perience as follows: “They promised me a job and took me to Rawal-
pindi. They drugged me, made me unconscious for days and cut out 
my kidney.”44 In order to support Ali’s pursuit of compensation or legal 
remedy, his father has taken loans, sold his goats, crockery, and 
bricks.45 All three people arrested for the incident were released after 
they produced documents showing that Ali had been paid USD $1250 
for his kidney.46 Ali is one of many who have fallen prey to this scenario, 
and the social consequences of selling a kidney or other organ can be 
as permanent as the loss of the organ itself.47 Men have returned to 
their communities only to find that they are no longer marriageable 
because they are not considered “whole,” and they are discriminated 
against by their employers because of beliefs that once one loses a kid-
ney they never regain full strength.48 These social consequences often 
place the individual in an even more dire financial situation.49 A 2002 
study on the long-term effects of organ sales in India revealed that, of 
three-hundred and fifty people who had sold their kidneys for an aver-
age price of $1000, seventy-five percent were still in debt six years after 
the sale, and the number of individuals living in poverty within the 
                                                                                                                      
42 Poor Villagers, supra note 3. 
43 Id. 
44 Id. 
45 Id. 
46 Id. 
47 Poor Villagers, supra note 3; Julie A. Corwin, World: The Risks, Benefits of a Free Market in 
Organs, Radio Free Europe Radio Liberty, May 16, 2006, http://www.rferl.org/features- 
article/2006/05/837d8204-b7c6-439f-9edc-cfa98f6c756f.html. 
48 See id. Anthropologists Nancy Scheper-Hughes and Lawrence Cohen are members of a 
task force of social scientists and anthropologists dedicated to investigating and exposing the 
organ trade and the ways in which it exploits the poor in foreign countries. Kathleen Scalise, 
Extreme Research: Nancy Scheper-Hughes and Lawrence Cohen, Berkeley Mag., Summer 1999, 
available at http://www.berkeley.edu/news/magazine/summer_99/feature_darkness_scheper. 
html. In India, poor women have sold their kidneys to pay back money borrowed to feed their 
families. Id. In South Africa, cadavers of poor, mostly minority, victims of violence have been 
"looted" for usable eyes and heart valves. Id. In Brazil, the government declares everyone a 
universal organ donor at birth, and people in poverty are terrified of falling prey to the organ 
trade. Id. 
49 See Jeffrey P. Kahn, Studying Organ Sales: Short Term Profits, Long Term Suffering, 
CNN.com, Oct. 10, 2002, http://archives.cnn.com/2002/HEALTH/10/01/ethics.matters. 
selling.organs. 
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study group had actually increased from fifty-four to seventy-one per-
cent.50 
II. The Promise of Stem Cell Research and the Perpetuation  
of Minority Disadvantage 
 The organ shortage and, more specifically, its effects on minority 
populations are daunting realities that should weigh on and inform 
both the legislature and the executive as stem cell policy is developed.51 
Within recent years the promise of stem cell research has grown as re-
search efforts have shifted from basic science to the development of 
cures for numerous diseases and disorders.52 Because all stem cell 
therapies, from cures for Alzheimer’s and diabetes to transplantable 
organs, will be genetically specific and will thus require “matching,” the 
same genetic issues that define minority disadvantage in the organ 
shortage will define their access to all stem cell therapies unless preven-
tative measures are taken.53 
 To date, the dominant moral concern in the stem cell debate has 
had little or nothing to do with securing equitable access to stem cell 
therapies, but has focused instead on whether it is acceptable practice 
to extract stem cells from live embryos.54 In 2001, President Bush took 
a determined moral stance on the issue when he announced that fed-
erally funded stem cell research could proceed but would be re-
                                                                                                                      
50 Id. The study also found that “[m]ore than 85 percent reported that their health 
declined after the donation, and almost 80 percent said they would not recommend selling 
a kidney.” Id. 
51 See Faden, supra note 1, at 17. 
52 See, e.g., id. at 13. Because of their unique capability to develop into numerous spe-
cialized cells, stem cells will potentially cure Alzheimer’s, Parkinson’s, and diabetes, as well 
as generate organs. See id. 
53 See id. 
54 See Geoffrey Winn, The Stem Cell Debate, L. Spot, Sept. 2001, http://www.law4u.com. 
au/lil/ls_stem.html. Pope John Paul II has stated: “Human embryos obtained in vitro are 
human beings and are subjects with rights; their dignity and right to life must be respected 
from the first moment of their existence. It is immoral to produce human embryos des-
tined to be exploited as disposable biological material.” See id. The Catholic Church’s opin-
ion, as stated by the late Pope John Paul II, is representative of many groups and centers 
on the conviction that an embryo is a human life, and thus that the destruction of an em-
bryo is a moral and legal wrong. Id. Winn also points to writer Ronald Bailey as a scholar 
who has convincingly opposed the stance taken by the Catholic Church and many others. 
Id. Bailey urges that while a one-week-old embryo is undeniably alive on a cellular level, 
molecular biology has recently established that the capacity for life is contained not only 
within an embryo, but also within adult cells, and thus, the potential for life is no longer a 
sufficient argument to legally protect human embryos from being “exploited” for the use 
of their stem cells. Id. 
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stricted to cell lines then in existence.55 As research continues to re-
veal more suitable means of harvesting stem cells, the efforts to utilize 
them for therapeutic purposes will ultimately forge on, and most of 
the contention regarding right to life issues will most likely dissipate.56 
 Unfortunately, the ethical dilemmas do not stop at the use of live 
embryos for obtaining stem cells; the debate has overlooked the reality 
that, unless proactive measures are implemented, minority and impov-
erished populations stand to be seriously disadvantaged yet again once 
stem cell research yields cures and therapies for diseases and disor-
ders.57 This threat is two-fold: (1) the same genetic issues that currently 
diminish the chances of minorities finding healthy organs that are a 
“match” will also prevent them from obtaining stem cell therapies that 
are a “match,” and (2) the race to patent the results of stem cell re-
search will inevitably lead to the commercialization and more expensive 
therapies, out of the reach of impoverished populations.58 In order to 
avoid these threats, Congress must develop proactive legislation regard-
ing stem cell research and related therapies. 
A. Immune Rejection and Biological Access 
 It is well understood that biological factors coupled with the 
“match” system of organ allocation has disadvantaged minority popula-
tions in need of organ transplants.59 The government must now under-
                                                                                                                      
55 See id. 
56 See Nicholas Wade, Stem Cell News Could Intensify Political Debate, N.Y. Times, Aug. 24, 
2006, at A1. On August 23, 2006, researchers at Advanced Technology, Inc. announced 
that they had discovered a new means by which stem cells could be extracted from an em-
bryo while allowing for the embryo to be implanted in the uterus and to develop into a 
fetus. See id. This approach, if proven successful in other laboratories, could potentially 
provide an answer to the stem cell debate insofar as it would quash ethical concerns re-
garding the destruction of potential life. Id. The new technique would be performed on a 
two-day-old embryo consisting of only eight cells and would involve one of those cells be-
ing removed while the embryo, now consisting of seven cells, could be implanted into the 
uterus to develop. Id. This process has been utilized for over ten years now in order to 
diagnose Down syndrome in embryos and, throughout that period, has yielded healthy 
babies. Id. Until this breakthrough, stem cells have been harvested from blastocysts, which 
are 150-cell embryos at a later stage of development; harvesting stem cells from blastocysts 
kills the embryo and gives rise to the ethical dilemma now fueling the stem cell research 
debate. Id. 
57 See Faden, supra note 1, at 17. 
58 See id.; Peter Yun-Hyoung Lee, Inverting the Logic of Scientific Discovery: Applying Com-
mon Law Patentable Subject Matter Doctrine to Constrain Patents on Biotechnology Research Tools, 
19 Harv. J.L. & Tech. 79, 103 (2005). 
59 Organ Donation Allocation Before the Senate Labor and Human Resources Committee and the 
House Committee on Commerce, 105th Cong. (1998) (testimony of Hon. Donna E. Shalala, Sec-
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stand and guard against the likelihood that the same issues will disad-
vantage minorities when stem cells are successfully developed into 
transplantable tissue.60 For, although stem cells are unspecialized in a 
very significant sense, they still have biological properties that make 
them suitable for some populations but not others.61 Ruth Faden, in 
her article Public Stem Cell Banks: Considerations of Justice in Stem Cell Re-
search and Therapy, calls the discriminatory result of such properties the 
problem of “biological access” —the situation in which “the biological 
properties of cells make them less accessible to some potential recipi-
ents than to others.”62 Immune rejection is a large part of the reason 
that minorities have been disadvantaged in their pursuit of healthy or-
gans to date, and it stands to limit minority access to stem cell therapies 
in the same way.63 
 A person’s genetic makeup includes a set of genes which code for 
a type of protein, called human leukocyte antigens (HLA), found on 
the surface of every cell in the body, including stem cells.64 HLA pro-
teins play a major role in immune recognition and rejection.65 Multiple 
genes code for HLA, and every person has two copies of these genes, 
one gene inherited from each parent.66 These HLA-coding genes occur 
in variant forms, each of which is called an allele, and the array of al-
leles that each person possesses is called her haplotype.67 Those with 
more common haplotypes are more likely to find a donor while those 
with less common haplotypes are less so.68 While mismatched trans-
plants can be and are performed between donors and recipients with 
different haplotypes, a greater number of mismatched alleles between 
the donor and the recipient results in a greater chance of organ failure 
or rejection.69 
                                                                                                                      
retary, U.S. Dept. of Health and Human Servs.), available at http://www.hhs.gov/asl/testify/ 
t980618a.html (addressing the Congress and describing the reasons for minority disadvan-
tage in the organ shortage). 
60 See Faden, supra note 1, at 17. 
61 Id. 
62 Id. at 14. 
63 Id. at 17. There are three main strategies currently implemented to remedy the prob-
lem of immune rejection: immunosuppressive drugs, clinically induced tolerance, and HLA 
matching. Id. at 16. 
64 Id. at 14. 
65 Faden, supra note 1, at 14. 
66 Id. 
67 Id. 
68 Id. at 15. 
69 Id. Faden explains that rejection is a major research area in the transplantation 
realm as researchers continue to seek a way to allow patients, regardless of their haplo-
types, to receive a transplant that will work for them. Id. If this research is successful, the 
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 Interestingly, “HLA has been demonstrated to track with geo-
graphical ancestry,” and persons of sub-Saharan African ancestry have 
the greatest variety of HLA types relative to any other geographical or 
ethnic group.70 The issue of HLA-matching thus poses a real problem 
for ethnic and minority communities in the United States because 
their HLA types are more varied than the HLA types of other social 
sectors, and so they are more rarely occurring in the United States 
population.71 Minorities will therefore be less likely to find a match, 
more likely to have a significant number of mismatches, and more 
likely to suffer failure or rejection.72 Faden points out that this unfor-
tunate genetic circumstance will extend from organ and bone marrow 
transplantation to stem cell transplants because stem cells bear the 
haplotype of the individual from whom the cell line was derived.73 
Thus, “disparities currently present in the field of transplantation are 
likely to be replicated in the emerging practice of stem cell transplan-
tation, unless specifically guarded against.”74 The federal government, 
in developing stem cell research policy, should prevent future dispar-
ity in access to stem cell therapies by requiring the use of diverse stem 
cell lines in federally funded research.75 
                                                                                                                      
concept of biological access may cease to exist, but for now, the problem of immune rejec-
tion is a very real obstacle to successful transplantation. Id. Currently, however, immuno-
suppressive drugs are the most widely used strategy to deal with immune rejection. Id. at 
16. In many cases, transplant recipients require continual immunosuppressive therapy in 
order to avoid either acute rejection or failure. Id. But the continuous ingestion of immu-
nosuppressive drugs is not without its own risks which include nephrotoxicity (poisonous 
effect of the medication on the kidney), diabetic and vascular tendencies, and an in-
creased risk of infection. Id. Others have echoed Faden’s concern that issues of HLA-
matching will prove prohibitive to many individuals seeking stem cell therapies. See Anver 
Kuliev et al., Preimplantation Genetics: Improving Access to Stem Cell Therapy, 1054 Annals N.Y. 
Acad. Sci. 223, 223 (2005). 
70 Faden, supra note 1, at 15. 
71 Id. 
72 See id. 
73 Id. at 17. The author further explains that HLA-matching will undoubtedly be more 
crucial to some stem-cell-derived therapies than to others depending on the tissue that is 
transplanted, but “matching will be critical to clinical success in at least some important 
therapeutic applications.” Id. 
74 Id. 
75 See Faden, supra note 1, at 17. 
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B. The Patent Problem 
 The issue of biological access is not the only obstacle that stands 
to inhibit minority access to stem cell therapies.76 Currently, one pat-
ent holder dominates the realm of stem cell research and could quite 
possibly monopolize the stem cell therapy market in the future.77 The 
race to discover, patent, and commercialize new stem cell therapies, if 
left unregulated, will probably result in those therapies being too ex-
pensive for minority and impoverished populations.78 Here, the Bayh-
Dole Act, which states the preservation of public availability of inven-
tions as one of its objectives, speaks to the government’s awareness of 
the ways in which patents can result in the inequitable use of scientific 
discovery—now they must translate that awareness into federal policy 
that will prevent that result in the future of stem cell research.79 
 Both common law and statutory law have established that, in order 
for a patent to create an exclusive right to investigate particular scien-
tific phenomena and theories, it must: (1) claim a specific device and 
not a general effect, and (2) not limit the use of a technological device 
that has no substitute and is necessary for the exploration of a certain 
scientific question.80 In the race to patent the results of stem cell re-
search, it is unclear whether the patents that have been issued to date 
are in keeping with these criteria.81 What is clear, however, is that if pat-
                                                                                                                      
76 See Lee, supra note 58, at 89–90 (explaining that currently stem cell research patents 
are held primarily by one entity, thus patent monopoly is a potential problem). 
77 Id. 
78 Joseph Mueller, Claims as Pointers: The Statutory Approach to Claim Construction, 12 J. 
Intell. Prop. L. 501, 509 (2005) (explaining that patent monopolies create higher prices 
because of greater demand than supply). 
79 35 U.S.C. § 200 (2001). 
80 Lee, supra note 58, at 83–84. The author explains that the prohibition against pat-
enting natural laws and phenomena is largely the result of common law. Id. at 93. The 
Supreme Court, in 1842, stated that “the end to be accomplished is not the subject of a 
patent,” but the new and useful means for obtaining that end are within the proper scope 
of patent law. Carver v. Hyde, 41 U.S. 513, 519 (1842). The Court has thus generally dis-
tinguished between a nonpatentable means and a patentable end. See Lee, supra note 58, 
at 93. 
81 Id. at 80–81. Lee argues that the patents currently limiting stem cell research are not 
in keeping with these criteria. See id. Lee distinguishes between upstream and downstream 
research assets and argues that such a distinction is at the heart of the patent system and is 
an effective embodiment of common law patent doctrine as well as sound public policy 
meant to encourage scientific innovation while protecting access to basic scientific knowl-
edge. Id. at 81–82. In order for researchers and innovators to be able to freely explore and 
implement their ideas, basic research tools and tools without substitutes (upstream knowl-
edge) must remain widely available. See id. At the same time, in order for researchers and 
innovators to have incentive to pursue their ideas, they are given exclusive rights (down-
stream privatization) to their final and unique invention. See id. 
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ent-monopolizing private companies commercialize the results of their 
stem cell research, access to stem cell therapies will be severely limited 
by the high price that will inevitably result from monopoly over a spe-
cific therapy.82 
 James Thomson was the first researcher to isolate human embry-
onic stem cells (HESCs).83 He subsequently secured three incredibly 
broad patents related to his discovery, which were eventually assigned 
to Geron Corporation, a private biotechnology firm.84 Thomson’s pat-
ents involve numerous claims stipulating what will be in violation of the 
patents; one of these claims alone encompasses, in effect, virtually all 
HESCs of significant research value.85 Arguably, these patents violate 
the common law patent qualification factors outlined above because 
isolated HESCs are a research tool with no adequate substitute and 
their patenting limits many other researchers from exploring the scien-
tific questions surrounding stem cells.86 The limitations placed on stem 
cell research by Thomson’s patents are substantial; because of the 
breadth of Thomson’s patents, all researchers must negotiate with the 
patent holder before using HESCs, even if they have isolated new 
HESCs or use a new method to do so.87 
                                                                                                                      
82 Mueller, supra note 78, at 509; see Lee, supra note 58, at 102–03. Insofar as HESCs are 
a research tool lying anterior to knowledge and theory, patents on HESCs have the practi-
cal effect of creating monopolies over the knowledge that such a tool will ultimately gen-
erate. Lee, supra note 58, at 102–03. Lee therefore urges that common law doctrine and 
public policy require a narrowing of the patentability of HESCs. See id. at 104. 
83 See Lee, supra note 58, at 89. 
84 Id. Lee argues that a patent on HESCs is a patent on an upstream research tool cre-
ating an incredibly “wide zone of exclusivity,” since the many discoveries and innovations 
that may arise from stem cell research are still largely theoretical and will be pursued well 
into the future. Id. at 92. Because HESCs are critical to achieving fundamental new insights 
into biology and are the means that will be used to explore numerous potential therapies, 
granting individual property rights over them seems contrary to the policy objective in 
keeping basic scientific knowledge available to the public at large and to the scientific 
community intent on pursuing innovation. Id. 
85 Id. at 90. 
86 Id. For Lee, stem cells are prime examples of upstream research tools, with no ade-
quate substitution, that should not be patentable in keeping with the common law. Id. at 
82. 
87 Christopher Hazuka, Supporting the Work of Lesser Geniuses: An Argument for Removing 
Obstructions to Human Embryonic Stem Cell Research, 57 U. Miami L. Rev. 157, 178–79 (2002) 
(explaining that the breadth of Thomson’s patents empowers him to control future stem 
cell research); see Lee, supra note 58, at 90. Thomson assigned his patents to the Wisconsin 
Alumni Research Foundation (WARF) which continues to hold the rights. Lee, supra note 
58, at 90. Even though Thomson’s inventive step merely involved discovering the method 
by which HESCs could be isolated and cultured (a process that might very well have an 
adequate substitute), his patents actually cover both the process and the stem cells them-
selves; the patents’ claims cover all HESCs instead of covering only those cell lines isolated 
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 By severely limiting the stem cell research tools available to others, 
the Thomson patents have laid the foundation for a future monopoly 
over stem cell therapies.88 The threat of patent infringement lawsuits 
has even discouraged foreign biotechnology companies and research 
institutions from marketing their stem cell advances within the United 
States.89 If their stem cells match the claims contained in the Thomson 
patents, a license must be secured from the patent holder so as to avoid 
patent litigation.90 While an agreement between the patent holder and 
the NIH has eased some concerns over the access to stem cell research 
tools, the agreement maintains the patent holder’s broad legal rights 
over HESCs, and does nothing to alleviate concerns that a future mo-
nopoly over stem cell research therapies derived from HESCs will dras-
tically increase prices, thereby making the therapies available only to 
the wealthy social sector.91 
                                                                                                                      
by Thomson. Id. The patent on the method for isolating and culturing stem cells also 
stands to hinder future research; even if another researcher successfully derived useful 
stem cells without infringing a patent claim, it would still be likely to infringe the patent on 
the only known method for maintaining the cells’ viability held by WARF. Id. 
In July 2006, the Foundation for Taxpayer and Consumer Rights, a California con-
sumer group, and the Public Patent Foundation, a New York organization advocating pat-
ent reform, petitioned the U.S. Patent and Trademark Office for review of the Thomson 
patents, and in October 2006 their request was granted. Andrew Pollack, Agency Agrees to 
Review Human Stem Cell Patents, N.Y. Times, Oct. 4, 2006, at C3. The review could lead to a 
rescission or narrowing of the three Thomson patents. Id. The groups who filed for the 
review argue that the patents should not have been granted to Thomson because, at the 
time of his application, three scientific papers by other researchers and one previous pat-
ent had already established the process by which embryonic stem cells could be isolated in 
mice, pigs, and sheep. Id. The patents, which only apply in the United States, have brought 
many research groups to move abroad, a clear indicator of the drastic ways in which the 
patents have impeded research efforts within the United States. Id. Even if the review re-
lieves this impediment, it could take years for the review to be completed. Id. 
88 See Lee, supra note 58, at 89–90; Hazuka, supra note 87, 175–76. 
89 Lee, supra note 58, at 90–91; Sheryl Gay Stolberg, Patent on Human Stem Cells Puts 
U.S. Officials in Bind, N.Y. Times, August 17, 2001, at A1. 
90 Lee, supra note 58, at 90. 
91 See id. at 90–91. In October of 1999, WARF established WiCell Research Institute, 
Inc., a non-profit organization designated to hold the licenses to WARF stem cells. Id. at 
90. WiCell executed a Memorandum of Understanding (MOU) which established that 
WiCell would offer WARF cells to scientists at NIH laboratories at the cost of preparation. 
Id. WiCell also agreed to allow federally funded non-profit researchers access to the stem 
cell lines upon negotiating similar arrangements. Id. Though this agreement provides 
more access to the patented stem cells, it includes strict “reach-through” provisions for 
commercial applications. Id. at 90–91. The agreement allows researchers using WARF 
HESCs to patent any discoveries made in their research but prohibits the commercializa-
tion of such discoveries unless a license with WARF is negotiated. Id. This stipulation alone 
should make it abundantly clear that WARF has no intention of loosening its grip on the 
future market in stem-cell-derived therapies. See id. Moreover, the MOU is a voluntary 
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III. Ensuring Equitable Access to Stem Cell Therapies Via 
Sound Federal Policy 
 Issues of biological access and the potential of future monopoliza-
tion of stem cell therapies by patent holders are pressing concerns be-
cause they will impinge equal access to stem cell therapies unless fed-
eral policy regarding stem cell research addresses these foreseeable 
problems.92 Faden points out that the public policy responses to the 
issues faced by minorities in their pursuit of healthy organs have largely 
focused on appealing to the African American community for donation 
and to strategies to increase overall donation.93 In the case of stem cell 
research, however, the availability and diversity of HLA types repre-
sented in the efforts need not be constrained by the vagaries of organ 
donation.94 Though technology currently cannot create organs for 
transplantation, it can create stem cell lines to be used for research and 
eventually therapies.95 Thus, “it is within our power to construct a bank 
of stem cell lines that includes a wide spectrum of HLA types, specifi-
cally selected to satisfy considerations of justice.”96 Because of the Bayh-
Dole Act, the government has an opportunity to ensure now that pat-
ented stem cell therapies will be both biologically and financially avail-
able to all in the future—that they will be used for the public good in 
general.97 
 President Bush’s 2001 decision that stem cell research could only 
continue on then-existing stem cell lines (twenty-one total), and his 
more recent veto of federal legislation that would have provided federal 
funding to stem cell research efforts, demonstrate not only that his pol-
icy is ill-informed, but that it is short-sighted.98 In issuing his veto, the 
President said nothing of patent concerns or biological realities, nor 
did he recognize that research firms were willing and able to move 
                                                                                                                      
agreement that allows WiCell to “exclude any party from using HESCs, charge whatever 
license fee it desires for their use, or pursue infringement suits against those who use the 
HESCs without its permission.” Id. at 91. Lee points out that the MOU is particularly ad-
vantageous to WiCell, which retains all rights to commercialize any discoveries arising from 
federally funded, basic research. Id. Thus, “WiCell’s apparent generosity in allowing at-cost 
access to its patented cells may ultimately prove quite self-rewarding.” Id. 
92 See Lee, supra note 58, at 103; Faden, supra note 1, at 17. 
93 See Faden, supra note 1, at 17 
94 See id. 
95 See id. 
96 See id. 
97 See 35 U.S.C. § 203(a) (2001). 
98 Dana Bash & Deirdre Walsh, Bush Vetoes Embryonic Stem-Cell Bill, CNN.com, Sept. 25, 
2006, http://www.cnn.com/2006/POLITICS/07/19/stemcells.veto. 
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overseas to continue their efforts.99 Shortly after the veto, the Geron 
Corporation, sole assignee of the Thomson patents, announced that it 
was relocating to the U.K. and noted funding support as one of its rea-
sons.100 In other words, stem cell research will progress with or without 
federal approval.101 There is a limited window of opportunity in which 
domestic research can be guided to achieve future equality in access to 
stem cell therapies, and that window is open now.102 
 In order for the policy goal of equal access to be achieved, the fed-
eral government must (1) fund stem cell research, (2) guide research 
efforts to involve diverse stem cell lines, and (3) prevent patent mo-
nopolies that will drive up the price of future therapies.103 If effective 
and remedial federal policy is implemented now, Americans will not 
only have access to affordable, biologically suitable therapies, but will 
have no reason to partake in the exploitation of impoverished minority 
populations abroad.104 
A. Stem Cell Banks 
 Because the same biological factors that prevent minorities from 
having sufficient access to transplantable organs currently will limit 
their access to stem cell therapies in the future, Congress should pass 
legislation requiring the collection of diverse stem cell lines.105 Con-
gressional legislation providing federal funds to stem cell research can 
then condition receipt of federal funds by research institutions on the 
use of diverse cell lines.106 Faden and her colleagues describe the stem 
cell lines currently available to researchers in the United States as “woe-
fully inadequate” because a mere twenty-one stem cell lines have been 
approved for federally funded research, and these stem cells were de-
rived from embryos created by in vitro fertilization for reproductive 
use.107 Because individuals engaged in the process of in vitro fertiliza-
                                                                                                                      
99 See id.; Mitchell, supra note 24. 
100 See Mitchell, supra note 24. 
101 See id. 
102 See id. 
103 See cases cited supra note 26; Mueller, supra note 78, at 509. 
104 See Faden, supra note 1, at 17 (explaining that the establishment of a diverse stem 
cell bank will render stem cell therapies available to minority populations); supra notes 41–
48 and accompanying text (describing the exploitation of the poor in foreign organ mar-
kets). 
105 Faden, supra note 1, at 17. 
106 See cases cited supra note 26. 
107 Faden, supra note 1, at 17. 
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tion are generally not minorities,108 such details lead to the logical con-
clusion that the diversity of HLA types currently being studied in the 
United States is incredibly limited.109 In order to remedy the current 
dearth of HLA-type diversity in stem cell lines available for research, 
stem cell banks, like those proposed by Faden, should be created.110 
B. Establishing March-in Rights Under the Bayh-Dole Act 
 Providing federal funds for stem cell research will not only allow 
the federal government to direct the researchers to use diverse stem 
cell lines, but will also establish their march-in rights under the Bayh-
Dole Act.111 March-in rights give the federal government (1) a nonex-
clusive license to whatever patented technology is derived from feder-
ally funded research, and (2) the right to, in some cases, grant third 
parties licenses to the invention against the patent-holder’s wishes.112 
These rights will be key to guarding against monopolization and exor-
bitant prices of stem cell therapies.113 Congress passed the Bayh-Dole 
Act in 1980 in order to encourage the commercialization of technolo-
gies developed using federal funds by giving researchers the right to 
patent federally funded inventions.114 The Act simultaneously created 
                                                                                                                      
108 B. J. Bankowski et al., Racial Disparities Amidst In Vitro Fertilization (IVF) Insurance 
Mandates in the United States, 84 Fertility & Sterility S242–43 (Supp. 2005). Minorities 
generally have less access to infertility treatments because of geographic and economic 
factors. Id. at S242. Moreover, state legislation requiring insurance companies to cover the 
procedures has been ineffective in increasing minority access to infertility care. Id. at S243. 
109 See Faden, supra note 1, at 17. 
110 Id. at 23. Faden proposes the creation of two stem cell banks. Id. The research bank 
would disburse cell lines for research and should thus be designed to fit research needs; it 
should consist primarily of homozygous (having identical alleles for a single trait) stem cell 
lines for the most widely occurring haplotypes in America. See id. Still, this bank should in-
clude several homozygous stem cell lines common to minorities so that diseases that occur 
primarily in minority populations are not left without a therapy in the future. See id. The 
therapeutic bank would disburse stem cells to clinicians to create a therapy for a specific 
individual. See id. at 18. Ideally, this bank would be sufficiently diverse so that every potential 
recipient could receive a match, but the funding required to establish and maintain such a 
bank renders this option currently unfeasible. See id. Given financial constraints, the most 
common haplotypes from each of the major minority populations in the United States 
should be included so that an equal percentage of individuals from each group will have 
access to stem cell therapies. Id. at 19, 21–23. 
111 35 U.S.C. §§ 202(c)(4), 203 (2001) (establishing march-in rights); see supra notes 
57, 58, and 78 and accompanying text. 
112 Id. §§ 202(c)(4), 203. 
113 Id. § 202(c); see supra notes 57, 58, and 78 and accompanying text. 
114 35 U.S.C. § 200. Prior to 1980, there was a “free market technology-transfer policy 
in the United States” based on the notion that, if public funds created the technology, title 
to the invention should remain with the government and the public. Peter S. Arno & Mi-
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an obligation of the patent holder to ensure that her technology would 
be available to the public on reasonable terms.115 Thus, Bayh-Dole pat-
ent-holders are subject to march-in rights, or the right of the govern-
ment to require the patent holder to assign a license to a party of their 
designation, which the government may exercise if the patentee fails to 
take reasonable steps toward practical application of the invention or if 
the action is necessary to satisfy health or safety needs.116 
 In order for the government to exercise march-in rights, an ag-
grieved party (usually one who desires access to the patented technol-
ogy) must file a petition with the NIH requesting that it initiate march-
in proceedings.117 The NIH then reviews the petition and the evidence 
and issues a decision appealable in federal court.118 Because march-in 
rights have only been petitioned for three times since 1980 and none of 
the petitions has been successful, there is significant disagreement over 
what warrants the exercise of march-in rights.119 In rejecting the three 
petitions, the NIH stated that it was uncomfortable using march-in 
rights to control the prices of pharmaceutical drugs.120 Still, there is 
reason to believe that the statute’s requirements of “practical applica-
tion” and availability on “reasonable terms” do authorize the govern-
ment to exercise march-in rights when prices of therapies are exorbi-
tant.121 Scholars who support this interpretation look to numerous 
court decisions in which the phrase “reasonable terms” has been inter-
                                                                                                                      
chael H. Davis, Why Don’t We Enforce Existing Drug Price Controls? The Unrecognized and Unen-
forced Reasonable Pricing Requirements Imposed upon Patents Deriving in Whole or in Part from 
Federally Funded Research, 75 Tul. L. Rev. 631, 640 (2001). 
115 35 U.S.C. § 203(a); Statement of National Institutes of Health Before Senate Ap-
propriations Subcommittee on Labor, Health and Human Services, Education and Related 
Agencies, 108th Cong. (2001) (testimony of Maria Freire, Director, Office of Technology 
Transfer, NIH), available at http://stemcells.nih.gov/policy/statements/080101freire.asp. 
116 35 U.S.C. § 203(a). The Act also provides that march-in rights may be exercised if 
necessary to “meet requirements for public use specified by Federal regulations” or for fail-
ure of the patentee to comply with other sections of the Act. Id. § 203(a)(3); Aaron Miller, 
Repairing the Bayh-Dole Act: A Proposal for Restoring Non-Profit Access to University Science, 2005 B.C. 
Intell. Prop. & Tech. F. 93001 (Sept. 30, 2005), available at http:// www.bc.edu/bc_org/ 
avp/law/st_org/iptf/articles/index.html. 
117 35 U.S.C. § 203. 
118 Id. 
119 Compare Arno & Davis, supra note 114, at 649 (arguing that the language of Bayh-
Dole could be interpreted to allow the exercise of march-in rights for the purpose of price 
control), with John H. Raubitschek & Norman J. Latker, Reasonable Pricing—A New Twist for 
March-In Rights Under the Bayh-Dole Act, 22 Santa Clara Computer & High Tech L.J. 149, 
162 (2005) (asserting that the legislative history of Bayh-Dole does not support an inter-
pretation allowing the exercise of march-in rights to control prices). 
120 Raubitschek & Latker, supra note 119, at 157–59. 
121 Arno & Davis, supra note 114, at 651. 
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preted to include prices.122 The government can also exercise march-in 
rights if required for the public health; a broad interpretation of this 
provision might also support price control.123 Finally, there is a differ-
ence between stem cell therapies that promise to cure disease and rem-
edy organ failure and prescription medications meant to treat, but not 
cure, diseases—it seems far more unjust for economics to deny some 
individuals access to therapies that will cure them. 
 To date, the NIH has not had to consider whether the effective 
denial of life-saving therapies to impoverished populations would war-
rant the exercise of march-in rights, but the federal government 
should take the steps described herein to ensure that if and when that 
question arises in the future, it is not a hypothetical one.124 For if stem 
cell research efforts continue to be denied federal funding, those ef-
forts will likely render therapies untouchable to the federal govern-
ment and to many impoverished individuals and minority groups.125 
Therefore, in order to secure government access and the possibility of 
price control in the future, federal funds must be provided before 
stem cell research progresses without them. 
Conclusion 
 While Fabre and other scholars continue to grapple with the ques-
tion of what social justice requires in addressing the organ shortage, 
the government is charged with the difficult task of actually achieving 
that justice. Unfortunately, minority disadvantage in the organ shortage 
is largely out of the government’s control insofar as their disadvantage 
is primarily due to biological factors and failure to donate organs in 
higher numbers. The government is also in a precariously helpless 
situation from which to assist those who are not poor enough to qualify 
for Medicaid and not financially able to purchase health insurance, and 
thus unable to secure an organ transplant. But, in developing stem cell 
policy, the federal government has an unprecedented opportunity to 
create equal access to life-saving therapies in the future. Sound stem 
cell policy requires federal funding conditioned on the use of diverse 
cell lines by researchers. Such funding, under the Bayh-Dole Act, will 
simultaneously ensure that the government will have the power to di-
                                                                                                                      
122 Id. 
123 Raubitschek & Latker, supra note 119, at 167. 
124 Id. at 157–59 (explaining that the petitions for the exercise of march-in rights have 
involved medications used to treat cancer and AIDS). 
125 See id. at 167 (explaining that the government might control therapy prices via the 
other provisions of Bayh-Dole or by eminent domain). 
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rect stem cell research and to potentially engage in price control of the 
resulting therapies. Denying federal funds to stem cell research will not 
only impinge research efforts, but, more importantly, it will impinge 
the achievement of social justice. 
